Understanding how neurons maintain mitochondrial health across decades of high metabolic demand may be one of the most consequential questions in longevity science. A newly published review in Mechanisms of Ageing and Development focuses on a recently recognized component of cellular housekeeping — mitochondria-derived vesicles (MDVs) — and their potential role in both normal aging and neurodegenerative disease.
MDVs are nanoscale membrane-bound structures that bud selectively from mitochondria under stress conditions, packaging damaged proteins, lipids, and nucleic acids for delivery to lysosomes and other intracellular destinations. Unlike mitophagy — the wholesale degradation of entire dysfunctional mitochondria — MDVs enable targeted, surgical-precision removal of localized damage, allowing the organelle to remain functional. This review synthesizes current evidence showing that MDV formation may operate upstream of or in parallel with mitophagy, acting as an early-response sentinel before irreversible mitochondrial deterioration occurs. The authors also highlight how aging impairs intracellular trafficking and lysosomal function, which may degrade MDV efficiency. Under these conditions, damaged mitochondrial cargo may instead be exported via extracellular vesicles, potentially spreading inflammatory signals between cells.
This framing is scientifically important. The conventional mitochondrial quality control narrative — proteostasis, biogenesis, dynamics, mitophagy — is well-established, but MDVs represent a genuinely underappreciated layer that bridges acute mitochondrial stress and chronic age-related dysfunction. Neurons are particularly exposed given their extraordinary energetic demands, spatial complexity, and limited regenerative capacity. The inflammatory spillover hypothesis — damaged mitochondrial components appearing in extracellular vesicles and perturbing intercellular signaling — connects mitochondrial biology to neuroinflammation frameworks seen in Alzheimer's and Parkinson's research. The primary limitation here is that this is a narrative review synthesizing mechanistic and often preclinical data, not a clinical trial or meta-analysis. Causal directionality in humans remains to be established. Still, for the longevity field, MDVs represent a credible and underexplored therapeutic target.